AzTrials
AzTrials

Coronary Artery DiseaseNCT06790836

Correlation of FFR CT With Invasive FFR in Multi-ethnic Cohort- a Retrospective Study

An observational study of Coronary Artery Disease, run by Sandwell & West Birmingham Hospitals NHS Trust at 1 site in United Kingdom.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This study aims to examine the correlation between Fractional Flow Reserve (FFR) FFR Computed Tomography (CT) and invasive FFR in a real-world setting using retrospective analysis of existing data, providing practical insights directly applicable to patient care. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Coronary Artery Disease
How many people
500 participants
Where
1 siteUnited Kingdom
Study dates
1 May 2026to 1 Dec 2026
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: The existing CTCA database for patients treated at Sandwell and West Birmingham NHS Trust between January 1, 2019, and December 31, 2023, with the clinical team screening the database to identify patients who fit with the eligibility criteria.

Who may be able to join

  • •≥18 years
  • Stable •patients with suspected CAD
  • Patients who underwent CTCA, FFR CT and had an invasive FFR.
  • CTCA images of high-quality for analysis, with clear visualisation of coronary arteries and minimal artifacts.

Who cannot join

  • •<18 years of age
  • Did not undergo FFR CT
  • Inadequate quality/degraded CTCA images

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Vinoda Sharma, FRCP FESC FRCPE contact

0044 1215075841

vinodasharma@nhs.net

United Kingdom1 site, 1 recruiting
  • Sandwell and West Birmingham NHS Trust

    Birmingham, West Midlands, B71 4HJ

    Kelly Hard, 0044 121 507 4946, swbh.randd.sponsorship@nhs.net

    Vinoda Sharma, FRCP FESC FRCPE

    Recruiting

Other trials in United Kingdom

About this study

Official title: Correlation of Fractional Flow Reserve Computed Tomography (FFR CT) Findings With Invasive FFR in Coronary Artery Disease (CAD) in a Multi-ethnic Cohort- a Retrospective Study

This study aims to examine the correlation between Fractional Flow Reserve (FFR) FFR Computed Tomography (CT) and invasive FFR in a real-world setting using retrospective analysis of existing data, providing practical insights directly applicable to patient care. By confirming or examining the accuracy of FFR CT in a clinical setting, our analysis could support its broader adoption as a routine non-invasive diagnostic tool potentially (a) reducing the need for invasive testing (b) minimising associated risks, and(c) lowering healthcare costs and provide fresh insights into non-invasive coronary diagnostics. Our findings will also help understand the relevance of these tests across different ethnic groups and the population we serve.

Read the detailed description

This retrospective study will analyse the existing Computed Tomography Coronary Angiogram (CTCA) database for patients treated at Sandwell and West Birmingham (SWBH) National Health Service (NHS) Trust between January 1, 2019, and December 31, 2023, with the clinical team screening the database to identify patients who fit with the eligibility criteria.

The proposed study is a retrospective analysis of the clinical and imaging data over a five-year period in patients with stable chest pain (approximately 500 patients), who underwent CTCA, FFR CT, and invasive FFR at SWBH NHS Trust. The study will assess the correlation between these diagnostic measures. The aim of this investigation is to address the ongoing discrepancies in the diagnostic accuracy of FFR CT compared to the gold standard invasive FFR, which persist despite the increasing adoption of FFR CT in clinical practice. While initial trials indicated promising sensitivity and specificity for FFR CT, recent observational studies including one involving 2,298 patients who underwent FFR CT, reported varying positive and negative predictive values, with a low positive predictive value of 49% (24). This variability raised concerns about the reliability of FFR CT across different patient populations, and the real-world accuracy and cost-effectiveness of FFR CT remain subjects of ongoing debate.

This study aims to examine the correlation between FFR CT and invasive FFR in a real-world setting using existing data, providing practical insights directly applicable to patient care. By confirming or examining the accuracy of FFR CT in a clinical setting, our analysis could support its broader adoption as a routine non-invasive diagnostic tool potentially (a) reducing the need for invasive testing (b) minimising associated risks, and(c) lowering healthcare costs and provide fresh insights into non-invasive coronary diagnostics. Our findings will also help understand the relevance of these tests across different ethnic groups and the population the investigators serve.

The patient data will be identified by accessing the CTCA database, and the study will adhere to the STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) guidelines (25).

The eligibility criteria are as follows:

  • Patients aged 18 years and above.
  • Patients presenting to the hospital with stable chest pain.
  • Patients who have undergone both FFR CT and invasive FFR. Ethical approval will be obtained through the Integrated Research Application System (IRAS).

The patient's information will be collected by members of the research team, including demographic data such as age, gender, body mass index (BMI), and cardiovascular risk factors (e.g., smoking, hypertension, and diabetes). Vessel characteristics, including the coronary artery involved, location, and degree of stenosis, will also be recorded. Results of FFR CT and Invasive Coronary Angiogram (ICA) findings (if performed), as well as diagnostic performance metrics-sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy of FFR CT in comparison to invasive FFR-along with downstream testing and imaging data, will be extracted from the CTCA database. All data will be coded and anonymised to ensure patient confidentiality and stored on NHS Trust computers with individual, password-protected logins. Only members of the research team involved in the study will have access to these computers.

The investigators will ensure all data collected, stored, and used complies with data protection laws, including the General Data Protection Regulation (GDPR) and the UK Data Protection Act 2018. Patient information will be anonymised to maintain confidentiality. The data will be securely stored on NHS computers at SWBH and used solely for this research.

An overview of the patient cohort will be provided, including demographics and clinical characteristics. Additionally, a detailed comparison of the diagnostic accuracy of FFR CT versus invasive FFR will be presented, including sensitivity, specificity, PPV, NPV, and overall accuracy.

Furthermore, the correlation between FFR CT and invasive FFR values will be explored, with a focus on any significant findings or discrepancies that may arise, offering insights into the diagnostic performance of FFR CT in comparison to the gold standard.

Statistical analysis will be performed using SPSS software, version 27. Continuous variables will be presented as mean ± standard deviation (SD) and compared using the Mann-Whitney U test or Analysis of Variance (ANOVA), as appropriate. Categorical variables will be expressed as percentages and compared using the chi-square test. Sensitivity, specificity, PPV, and NPV will be calculated based on the correlation between FFR CT and invasive FFR.

Inclusion Criteria:

Patients meeting all the below criteria will be included.

•≥18 years

  • Stable •patients with suspected CAD
  • Patients who underwent CTCA, FFR CT and had an invasive FFR.
  • CTCA images of high-quality for analysis, with clear visualisation of coronary arteries and minimal artifacts.

Exclusion criteria:

Patients meeting any of the following criteria will be excluded.

  • <18 years of age
  • Did not undergo FFR CT
  • Inadequate quality/degraded CTCA images Online database on password protected NHS TRUST computer to collect demographic parameters of all patients i.e. age, sex, BMI along with history of disease, coexisting morbidities like hypertension, diabetes and hyperlipidaemia procedural and outcome information.

Demographics (age, gender, ethnicity socio economic status), BMI and cardiovascular risk factors) vessel characteristics, FFR CT values and invasive FFR values will be obtained.

Categorical variables will be compared by chi square test or Fisher's test and continuous variables will be compared by Mann Whitney U test Ethical approval for this retrospective study will be obtained through IRAS application.

References

  1. Organization WH. Cardiovascular diseases (CVDs) 2021 [Available from: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds).
  2. Writing Group M, Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, et al. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation. 2016;133(4):e38-360.
  3. Yamagishi M, Tamaki N, Akasaka T, Ikeda T, Ueshima K, Uemura S, et al. JCS 2018 Guideline on Diagnosis of Chronic Coronary Heart Diseases. Circulation Journal. 2021;85(4):402-572.
  4. Wolk MJ, Bailey SR, Doherty JU, Douglas PS, Hendel RC, Kramer CM, et al. ACCF/AHA/ASE/ASNC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2013 multimodality appropriate use criteria for the detection and risk assessment of stable ischemic heart disease: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2014;63(4):380-406.
  5. Douglas PS, Hoffmann U, Lee KL, Mark DB, Al-Khalidi HR, Anstrom K, et al. PROspective Multicenter Imaging Study for Evaluation of chest pain: rationale and design of the PROMISE trial. American heart journal. 2014;167(6):796-803. e1.
  6. CT coronary angiography in patients with suspected angina due to coronary heart disease (SCOT-HEART): an open-label, parallel-group, multicentre trial. The Lancet. 2015;385(9985):2383-91.
  7. Alfakih K, Byrne J, Monaghan M. CT coronary angiography: a paradigm shift for functional imaging tests. Open Heart. 2018;5(1):e000754.
  8. (NICE) NIfHaCE. HeartFlow FFRCT for estimating fractional flow reserve from coronary CT angiography. 2017.
  9. Cremer PC, Nissen SE. The National Institute for Health and Care Excellence update for stable chest pain: poorly reasoned and risky for patients. Heart. 2017;103(13):972-4.
  10. Pijls NHJ, De Bruyne B, Peels K, Van Der Voort PH, Bonnier HJRM, Bartunek J, et al. Measurement of Fractional Flow Reserve to Assess the Functional Severity of Coronary-Artery Stenoses. New England Journal of Medicine. 1996;334(26):1703-8.
  11. Achenbach S, Rudolph T, Rieber J, Eggebrecht H, Richardt G, Schmitz T, et al. Performing and interpreting fractional flow reserve measurements in clinical practice: an expert consensus document. Interventional Cardiology Review. 2017;12(2):97.
  12. Xaplanteris P, Fournier S, Pijls NHJ, Fearon WF, Barbato E, Tonino PAL, et al. Five-Year Outcomes with PCI Guided by Fractional Flow Reserve. New England Journal of Medicine. 2018;379(3):250-9.
  13. De Bruyne B, Pijls NHJ, Kalesan B, Barbato E, Tonino PAL, Piroth Z, et al. Fractional Flow Reserve-Guided PCI versus Medical Therapy in Stable Coronary Disease. New England Journal of Medicine. 2012;367(11):991-1001.
  14. Scoccia A, Tomaniak M, Neleman T, Groenland FTW, Plantes ACZD, Daemen J. Angiography-Based Fractional Flow Reserve: State of the Art. Current Cardiology Reports. 2022;24(6):667-78.
  15. Members TF, Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, et al. 2013 ESC guidelines on the management of stable coronary artery disease: The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. European Heart Journal. 2013;34(38):2949-3003.
  16. Kurata A, Fukuyama N, Hirai K, Kawaguchi N, Tanabe Y, Okayama H, et al. On-Site Computed Tomography-Derived Fractional Flow Reserve Using a Machine-Learning Algorithm - Clinical Effectiveness in a Retrospective Multicenter Cohort -. Circulation Journal. 2019;83(7):1563-71.
  17. Kimura T, Shiomi H, Kuribayashi S, Isshiki T, Kanazawa S, Ito H, et al. Cost analysis of non-invasive fractional flow reserve derived from coronary computed tomographic angiography in Japan. Cardiovascular Intervention and Therapeutics. 2015;30(1):38-44.
  18. Nørgaard BL, Leipsic J, Gaur S, Seneviratne S, Ko BS, Ito H, et al. Diagnostic performance of noninvasive fractional flow reserve derived from coronary computed tomography angiography in suspected coronary artery disease: the NXT trial (Analysis of Coronary Blood Flow Using CT Angiography: Next Steps). J Am Coll Cardiol. 2014;63(12):1145-55.
  19. Koo BK, Erglis A, Doh JH, Daniels DV, Jegere S, Kim HS, et al. Diagnosis of ischemia-causing coronary stenoses by noninvasive fractional flow reserve computed from coronary computed tomographic angiograms. Results from the prospective multicenter DISCOVER-FLOW (Diagnosis of Ischemia-Causing Stenoses Obtained Via Noninvasive Fractional Flow Reserve) study. J Am Coll Cardiol. 2011;58(19):1989-97.
  20. Gray AJ, Roobottom C, Smith JE, Goodacre S, Oatey K, O'Brien R, et al. Early computed tomography coronary angiography in patients with suspected acute coronary syndrome: randomised controlled trial. BMJ. 2021:n2106.
  21. Curzen N, Nicholas Z, Stuart B, Wilding S, Hill K, Shambrook J, et al. Fractional flow reserve derived from computed tomography coronary angiography in the assessment and management of stable chest pain: the FORECAST randomized trial. European Heart Journal. 2021;42(37):3844-52.
  22. Upadhyaya SGN, Santhirasekaram A, Dharas M, Yousif A, D'sa A, Das I, et al. OSCRIS; An Efficient and Patient preferred Cardiac CT service. Journal of Cardiovascular Computed Tomography. 2019;13(1):S9.
  23. (NHS) NHS. Innovation and Technology Payment. (2018-2021).
  24. Mittal TK, Hothi SS, Venugopal V, Taleyratne J, O'Brien D, Adnan K, et al. The Use and Efficacy of FFR-CT. JACC: Cardiovascular Imaging. 2023;16(8):1056-65.
  25. Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Journal of Clinical Epidemiology. 2008;61(4):344-9.
Keywords
FFR CT, Invasive FFR, Comparison
Medical subject headings
Coronary Artery Disease

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Correlation between FFR CT and invasive FFR.

    Correlation as mesured by positive predicitve value, negative predictive value, sensitivity and specificity

    Measured: 6 months

Secondary outcomes (1)
  1. Assess the downstream testing after FFR CT

    By assessing the rates and results of invasive coronary angiography

    Measured: 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Jan 2025
  2. Study start1 May 2026 (estimated)
  3. Primary completion1 Aug 2026 (estimated)
  4. Study completion1 Dec 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Retrospective
Enrolment
500 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06790836
Sponsor's protocol ID
IRAS #339186
Status last verified
May 2026
First submitted
18 Jan 2025
Last updated
7 May 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: This study involves a retrospective database analysis- on completion of analysis and write up, data can be shared on request

Questions about this trial

What is this clinical trial studying?

An observational study of Coronary Artery Disease, run by Sandwell & West Birmingham Hospitals NHS Trust at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 7 May 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Vinoda Sharma, FRCP FESC FRCPE (0044 1215075841, vinodasharma@nhs.net), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Correlation between FFR CT and invasive FFR. (time frame: 6 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 May 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in